|
|
 Previous Article | Table of Contents | Next Article 
A Recombinant Human scFv Anti-Rh(D) Antibody With Multiple Valences Using a C-Terminal Fragment of C4-Binding Protein
M. Tonye Libyh,
D. Goossens,
S. Oudin,
N. Gupta,
X. Dervillez,
G. Juszczak,
P. Cornillet,
F. Bougy,
B. Reveil,
F. Philbert,
T. Tabary,
D. Klatzmann,
P. Rouger, and
J.H.M. Cohen
From the Laboratoire d'Immunologie, UFR Médecine, Pôle Biomolécules URCA, Reims, France; the Institut National de Transfusion Sanguine, Paris, France; and UMR 107 CNRS, CERVI Hôpital Pitié Salpêtrière, Paris, France.
Monomeric recombinant molecules prove generally unsatisfactory for in vivo use. Most biological systems are indeed multivalent either structurally, associating different chains, or functionally, when cross-linked by their ligands. Mimicking natural molecules for immune intervention implies the need for multimerizing systems to create multivalent molecules capable of interfering with physiological processing. A multivalent anti-Rh(D) recombinant protein has been designed by reconstructing the antibody binding site of a human monoclonal anti-Rh(D) antibody as a single chain Fv mini antibody, then multimerizing it by inserting at its C-terminal end the C-terminal part of the C4 binding protein (C4bp) alpha chain, which is responsible for the octamer multimerization of that molecule. This soluble multivalent recombinant molecule was functional, bound red blood cells (RBCs), agglutinated them, and did not activate complement. This demonstration model opens the way for future in vivo use of multivalent molecules associating antibody valences and other functional molecules for cell targeting, imaging, or removal of cells such as Rh(D)-positive RBCs for preventing Rh alloimmunization.
Blood, Vol. 90 No. 10 (November 15), 1997:
pp. 3978-3983
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. A. Ogun, L. Dumon-Seignovert, J.-B. Marchand, A. A. Holder, and F. Hill
The Oligomerization Domain of C4-Binding Protein (C4bp) Acts as an Adjuvant, and the Fusion Protein Comprised of the 19-Kilodalton Merozoite Surface Protein 1 Fused with the Murine C4bp Domain Protects Mice against Malaria
Infect. Immun.,
August 1, 2008;
76(8):
3817 - 3823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goel, D. Colcher, J. Baranowska-Kortylewicz, S. Augustine, B. J. M. Booth, G. Pavlinkova, and S. K. Batra
Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application
Cancer Res.,
December 1, 2000;
60(24):
6964 - 6971.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Christiansen, P. Devaux, B. Réveil, A. Evlashev, B. Horvat, J. Lamy, C. Rabourdin-Combe, J. H. M. Cohen, and D. Gerlier
Octamerization Enables Soluble CD46 Receptor To Neutralize Measles Virus In Vitro and In Vivo
J. Virol.,
May 15, 2000;
74(10):
4672 - 4678.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Oudin, M. T. Libyh, D. Goossens, X. Dervillez, F. Philbert, B. Reveil, F. Bougy, T. Tabary, P. Rouger, D. Klatzmann, et al.
A Soluble Recombinant Multimeric Anti-Rh(D) Single-Chain Fv/CR1 Molecule Restores the Immune Complex Binding Ability of CR1-Deficient Erythrocytes
J. Immunol.,
February 1, 2000;
164(3):
1505 - 1513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
